Stay updated on Milademetan Safety in AML/MDS Clinical Trial

Sign up to get notified when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.
Latest website image capture
Clouds background image

Latest updates to the Milademetan Safety in AML/MDS Clinical Trial page

  1. Check
    6 days ago
    Change Detected
    Summary
    The page’s revision identifier has been updated to v3.5.3, replacing the previous v3.5.2. This reflects a platform update without changes to the shown study details.
    Difference
    0.0%
    Check dated 2026-04-30T18:41:33.000Z thumbnail image
  2. Check
    13 days ago
    No Change Detected
  3. Check
    20 days ago
    Change Detected
    Summary
    Revision updated from v3.5.0 to v3.5.2.
    Difference
    0.0%
    Check dated 2026-04-16T10:43:19.000Z thumbnail image
  4. Check
    27 days ago
    No Change Detected
  5. Check
    34 days ago
    Change Detected
    Summary
    Added Acute myeloid leukemia as a listed condition/keyword on the study page.
    Difference
    0.0%
    Check dated 2026-04-02T00:35:25.000Z thumbnail image
  6. Check
    49 days ago
    Change Detected
    Summary
    Revision: v3.5.0 was added and Revision: v3.4.3 was removed.
    Difference
    0.0%
    Check dated 2026-03-18T17:54:15.000Z thumbnail image
  7. Check
    56 days ago
    Change Detected
    Summary
    Site revision updated from v3.4.2 to v3.4.3.
    Difference
    0.0%
    Check dated 2026-03-11T15:49:49.000Z thumbnail image
  8. Check
    84 days ago
    Change Detected
    Summary
    Added Revision: v3.4.2 to the page; Removed the older funding notice (v3.4.1). These changes do not modify the study content, eligibility, endpoints, or results. To avoid being alerted by small changes, set an alert condition by clicking below.
    Difference
    0.4%
    Check dated 2026-02-11T05:13:26.000Z thumbnail image

Stay in the know with updates to Milademetan Safety in AML/MDS Clinical Trial

Enter your email address, and we'll notify you when there's something new on the Milademetan Safety in AML/MDS Clinical Trial page.